|
|
 |
John Fox, MD, MHA |
|
|
 |
Adam Friedman, MD, FAAD |
|
|
 |
Edmund Pezalla, MD, MPH |
|
|
Breakthrough Therapies in Dermatology Management – Advances in Atopic Dermatitis for Managed Care and Payer Professionals – Case Study 2
|
||||||||||||||
| Expert Faculty Author: | ||||||||||||||
|
||||||||||||||
Target Audience
The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Statement of Need/Program Overview
The evolving AD treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst managed care, specialty pharmacy, and other payer professionals to provide enhanced clinical and economic outcomes to beneficiaries with AD. In addition, payer decision makers need instruction on benefit design strategies that can support an improvement in overall outcomes in patients with AD.
Educational Objectives
Accreditation Information
|
Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, National Eczema Association, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-22-042-H01-P
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
| Name of Faculty or Presenter | Reported Financial Relationship |
| John Fox, MD, MHA | John Fox, MD, MHA has nothing to disclose. |
| Adam Friedman, MD, FAAD | Consulting fees (e.g. advisory boards) – Sanova Works, Amgen, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Pfizer, Biogen, Valeant Pharmaceuticals North America LLC, Intraderm Pharmaceuticals, Oculus Innovative Science, Inc., Novartis, Johnson and Johnson Consumer Products Company, Encore Dermatology, Inc., Exeltis, Promius Pharma, LLC., Eli Lilly and Company, Derrmira, Menlo Therapeutics, Ortho Dermatologics, Hoth Therapeutics, Greenway Therapeutix, Brickell Biotech, Inc. |
| Edmund Pezalla, MD, MPH | Consulting fees (e.g. advisory boards) – Pfizer, Sanofi Genzyme, Regeneron |
The PIM planners and managers have nothing to disclose.
The NEA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.
FEE INFORMATION